MedTrace Logo

Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer

NCT00702182 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-10-19

No results posted yet for this study

Summary

The purpose of this study is to define the schedule and dose of oral vinorelbine (Navelbine) to be used with erlotinib in non-small cell lung cancer.

Conditions

Interventions

DRUG

Vinorelbine (Navelbine)

Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule

DRUG

Vinorelbine (Navelbine)

Metronomic Schedule Oral Vinorelbine 3 times a week

DRUG

Erlotinib

Daily Oral Erlotinib 100 mg

Sponsors & Collaborators

  • National Cancer Centre, Singapore

    lead OTHER

Principal Investigators

  • Wan-Teck Lim, MD · National Cancer Center Singapore

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-04-30
Completion
2012-10-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00702182 on ClinicalTrials.gov